ResearcherOslo University HospitalActive in the last 2 years

Johannes R. Hov

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5900-8096; OpenAlex author ID A5087109628. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper

Papers 1

Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. Last author DOI 10.3389/fonc.2024.1488749 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Peder R. Braadland · 1 shared paper, 2024 · strength 0.23
- Paper Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. DOI 10.3389/fonc.2024.1488749 ↗
Sheraz Yaqub · 1 shared paper, 2024 · strength 0.23
- Paper Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. DOI 10.3389/fonc.2024.1488749 ↗
Ingvild Farnes · 1 shared paper, 2024 · strength 0.23
- Paper Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. DOI 10.3389/fonc.2024.1488749 ↗
Elin Hegland Kure · 1 shared paper, 2024 · strength 0.23
- Paper Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. DOI 10.3389/fonc.2024.1488749 ↗
Knut Jørgen Labori · 1 shared paper, 2024 · strength 0.23
- Paper Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. DOI 10.3389/fonc.2024.1488749 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.